Early Diagnosis and Results of Enzyme Replacement Therapy in the Patient with Mucopolysaccharidosis Type VI: Clinical Case
Background. Mucopolysaccharidosis type VI (MPS VI, Maroteaux–Lamy syndrome) is rare autosomal-recessive multisystem disease, one of the group of lysosomal storage diseases. The MPS VI pathogenesis is determined by arylsulfatase B enzyme deficiency caused by mutations in the ARSB gene. There are only...
Saved in:
| Main Authors: | Dmitry V. Ivanov, Anna I. Ostrun, Vladimir M. Kenis, Tatiana V. Markova, Ekaterina Yu. Zakharova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2021-12-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/2776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY
by: Liliia A. Osipova, et al.
Published: (2018-04-01) -
Hematopoietic stem cell transplantation in pediatric patients with type VI mucopolysaccharidosis
by: Vedat Uygun, et al.
Published: (2025-08-01) -
Results of 14-year-long Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II: Clinical Case
by: Natalia V. Zhurkova, et al.
Published: (2023-01-01) -
Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020-02-01) -
Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
by: Nato D. Vashakmadze, et al.
Published: (2021-12-01)